Try a new search

Format these results:

Searched for:

in-biosketch:true

person:zelefm01

Total Results:

483


Long-Term Urinary and Rectal Tolerance in Prostate Cancer Survivors Treated With Definitive Conformal Radiation Therapy [Meeting Abstract]

Knoll, M.; Pei, X.; Zelefsky, M. J.
ISI:000342331402499
ISSN: 0360-3016
CID: 5530932

Patterns of Failure in Patients With Head and Neck Carcinoma of Unknown Primary Treated With Radiation Therapy [Meeting Abstract]

Cuaron, J. J.; Rao, S. S.; Wolden, S. L.; Zelefsky, M. J.; Schupak, K. D.; Mychalczak, B.; Lee, N.
ISI:000342331402080
ISSN: 0360-3016
CID: 5530922

Image-Guided Intensity Modulated Radiation Therapy (IMRT) for Bladder Cancer: Toxicity and Early Outcomes [Meeting Abstract]

Kollmeier, M. A.; Thakker, N.; Zelefsky, M. J.; Bochner, B. H.; Dalbagni, G. M.; Bajorin, D. F.; Rosenberg, J. E.
ISI:000342331401538
ISSN: 0360-3016
CID: 5530912

Continuous Monitoring and Intra fraction Target Position Correction During Treatment Is Essential for Patients Undergoing SBRT Prostate Therapy With Tight Target Margins [Meeting Abstract]

Lovelock, D.; Messineo, A.; Cox, B. W.; Kollmeier, M. A.; Zelefsky, M. J.
ISI:000342331401484
ISSN: 0360-3016
CID: 5530902

Neuroendocrine Prostate Cancer: FOG-PET and Targeted Molecular Imaging [Meeting Abstract]

Spratt, D. E.; Zelefsky, M. J.; Fareedy, S.; Lindgren, S.; Osborne, J. R.
ISI:000342331400484
ISSN: 0360-3016
CID: 5530892

Prostate-Specific Antigen Bounce After Dose-Escalated Radiation Therapy for Prostate Cancer is an Independent Predictor for Distant Metastasis, Cancer-Specific Survival, and Overall Survival [Meeting Abstract]

Romesser, P. B.; Pei, X.; Spratt, D.; Zumsteg, Z.; Kollmeier, M. A.; Polkinghorn, W.; Zelefsky, M. J.
ISI:000342331400357
ISSN: 0360-3016
CID: 5530882

A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy

Yamada, Yoshiya; Kollmeier, Marisa A; Pei, Xin; Kan, Chu Cheng; Cohen, Gil'ad N; Donat, Sherri M; Cox, Brett W; Zelefsky, Michael J
PURPOSE/OBJECTIVE:We report the toxicity and biochemical tumor control outcome of a prospective Phase II study using high-dose-rate brachytherapy (HDR) alone as a salvage therapy for recurrent disease after external beam radiotherapy (EBRT). METHODS:Forty-two patients with biopsy-proven recurrence were enrolled on a Phase II study of salvage HDR monotherapy using iridium-192. Median pretreatment EBRT dose was 8100 cGy (6840-8640 cGy) and the median time from completion of EBRT to salvage HDR was 73 months. The protocol prescription dose of 3200 cGy was delivered in four fractions over 30 hours in a single insertion. Median followup after salvage HDR was 36 months (6-67 months). RESULTS:The actuarial prostate-specific antigen biochemical relapse-free survival and distant metastases-free survival rates at 5 years were 68.5% and 81.5%, respectively. Cause-specific survival was 90.3%. Late genitourinary Grade 1and 2 toxicities were found in 38% and 48%, respectively, and one patient developed Grade 3 urinary incontinence. Late Grade 1 and 2 gastrointestinal toxicity was noted in 17% and 8% of patients, respectively. Three patients (7%) developed Grade 2 late urinary toxicity (urethral stricture), which were corrected with urethral dilatation, and one patient developed Grade 3 urinary incontinence. No Grade 4 toxicities were observed. CONCLUSIONS:Genitourinary toxicity was the most commonly encountered toxicity observed after salvage HDR but severe toxicities were uncommon. Salvage HDR is an effective and well-tolerated modality for locally recurrent prostate cancer and should be considered even for patients who have previously been treated with ultra-high dose levels of EBRT.
PMCID:5718052
PMID: 24373762
ISSN: 1873-1449
CID: 5528812

Defining Long Term Failure Risk in Patients With an Undetectable PSA After Salvage Radiation [Meeting Abstract]

Abramowitz, M. C.; Williams, S. G.; Stephenson, A.; Kattan, M.; Pisansky, T. M.; Klein, E. E.; Anscher, M. S.; Michalski, J.; Sandler, H. M.; Forman, J. D.; Zelefsky, M. J.; Kestin, L.; DeWeese, T. L.; Liauw, S.; Valicenti, R. K.; Kuban, D. A.; Pollack, A.
ISI:000342331400298
ISSN: 0360-3016
CID: 5530872

Long-term Impact of Androgen Deprivation Therapy on Cardiovascular Morbidity after Radiotherapy for Clinically Localized Prostate Cancer [Meeting Abstract]

Kohutek, Z.; Steinberger, E.; Pei, X.; Zhang, Z.; Shi, W.; Kollmeier, M. A.; Zelefsky, M. J.
ISI:000342331400033
ISSN: 0360-3016
CID: 5530862

Improved long-term outcomes with IMRT: is it better technology or better physics? [Comment]

Zelefsky, Michael J; Deasy, Joseph O
PMID: 24267964
ISSN: 1879-355x
CID: 5528802